Amyotrophic lateral sclerosis (ALS) is a devastating disease. Once ALS develops, the motor neurons that control the movement of muscles gradually start to die off, causing paralysis of the muscles in the hand and leg.
The patient suffers from difficulty in using arms and legs, and in eating food and speaking. In about two to five years after the development of ALS, the muscles that control breathing are paralyzed, necessitating the support of a respirator. However, because the senses, memory, and cognitive functions remain normal, the patient is conscious of the progression of the disease.
Unfortunately, no effective treatment has been found. So far, research into understanding ALS has focused mainly on motor neurons. However, Koji Yamanaka, Unit Leader, and colleagues at the Brain Science Institute has focused on cells neighboring the motor neurons, and have met with success in their discovery that the glial cells cause damage to the nerve cells, thus accelerating the progression of the disease. This discovery shows great promise in the development of new treatments to prevent the progression of ALS.
ALS, an incurable disease that exclusively destroys motor neurons
In the spring of 1939, Lou Gehrig, a Major League Baseball player for the New York Yankees in the US, was mired in a prolonged batting slump. His fans and team-mates were very surprised because he was a real slugger, who enjoyed many seasons with high batting averages; his batting record included 23 grand slam home runs, a Major League record, and a consecutive game-playing streak of 2130. He was called "Iron Horse," but it was ALS that prevented him from continuing his playing streak. Lou Gehrig retired in June that year. Two years later he died young, at the age of 37 years.
In the US, ALS is known as 'Lou Gehrig's disease' and is one of the neurodegenerative diseases caused by the gradual death of nerve cells. In Alzheimer's disease, which is a well-known neurodegenerative disease, the patient develops dementia as a result of the gradual death of memory-related nerve cells. In ALS, in contrast, the patient becomes paralyzed because of the gradual death of the motor neurons in the brain and the spinal cord that control the muscles throughout the body.
There are about 6,000 patients with ALS and it is estimated that about 2,000 people may develop ALS every year in Japan. Patients with ALS develop the disease mostly at about 60 years of age, but young people can be affected, like Gehrig.
About 10% of patients with ALS develop the disease because they have inherited the causative genes, but no abnormal genes were found in the remaining 90%. "In other words, anybody can develop ALS," says Yamanaka, who has worked as a neurologist and has treated patients with ALS.
Neurologists are the medical doctors who have been trained in the diagnosis of diseases of brain, spinal cord, and muscle, and their treatment with drugs. In fact, however, there are many other diseases that cannot be treated with drugs because the causes are unknown. "I faced a big dilemma in clinical practice, seriously thinking, 'What can I provide for patients with ALS?' So, I thought I would like to elucidate the cause of the neurodegenerative disease to develop new cures."
Yamanaka trained and worked as a neurologist for four years. Then he devoted himself to basic research and started the study on ALS in 2001. Why did he select ALS as his subject of research? "I chose ALS because it is an incurable disease. ALS progresses quickly, and the symptoms of the patient worsen day by day. From the time the patient makes a clinical visit, he or she will be unable to walk within the first year, will be bed-ridden within the following year, and won’t be alive within three years from the first visit. I was greatly motivated by shocking experiences when I was responsible as a neurologist for treating patients with ALS."
Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory
How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
24.03.2017 | Materials Sciences
24.03.2017 | Physics and Astronomy
24.03.2017 | Physics and Astronomy